您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > NSC745885
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
NSC745885
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
NSC745885图片
CAS NO:4219-52-7
包装与价格:
包装价格(元)
5mg电议
10mg电议
50mg电议
100mg电议

产品介绍
NSC745885是一种有效的抗肿瘤(anti-tumor)试剂,对多种癌细胞株有选择性毒性,但对正常细胞没有毒性。NSC745885是一种有效的EZH2的下调因子通过蛋白酶体降解途径。NSC745885为晚期膀胱癌和口腔鳞癌的研究提供了可能性。
Cas No.4219-52-7
Canonical SMILESO=C(C1=C(C2=O)C3=NSN=C3C=C1)C4=C2C=CC=C4
分子式C14H6N2O2S
分子量266.27
溶解度DMSO:< 1 mg/mL (insoluble or slightly soluble) *NSC745885 is usually formulated as a suspension.
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers[1][2].

NSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the densities of cultured cells when compared with untreated cells. The IC50 of NSC745885 is 0.85 μM after 72 hours' treatment[1].NSC745885 (0.5-4 μM; 24 hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner[1].NSC745885 (0.5-2 μM; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells[1]. Cell Viability Assay[1] Cell Line: SAS cells is obtained from a poorly differentiated human squamous cell carcinoma

NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin[1]. Animal Model: Eight-week-old NOD/SCID (NOD.CB17 Prkdcscid/J) mice[1]

[1]. Chen YW, et al.A novel compound NSC745885 exerts an anti-tumor effect on tongue cancer SAS cells in vitro and in vivo.PLoS One. 2014 Aug 15;9(8):e104703. [2]. Tang SH, et al. Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo.Oncotarget. 2014 Nov 15;5(21):10342-55.